In a report released yesterday, Max Masucci from Canaccord Genuity maintained a Buy rating on T2 Biosystems (TTOO), with a price target of $3.50. The company’s shares closed last Tuesday at $2.81.
According to TipRanks.com, Masucci is a top 100 analyst with an average return of 92.7% and a 94.8% success rate. Masucci covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Genetron Holdings, and Guardant Health.
T2 Biosystems has an analyst consensus of Moderate Buy, with a price target consensus of $3.50.
See today’s analyst top recommended stocks >>
T2 Biosystems’ market cap is currently $276.7M and has a P/E ratio of -2.80. The company has a Price to Book ratio of 15.74.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types. It products include T2Bacteria Panel, T2Candida Panel, T2Dx Instrument, AND T2MR Technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.
